Rethinking QRS duration as an indication for CRT

Stavrakis et al. are to be congratulated on a meticulous analysis of major CRT trials and give us an elegant and simple parameter for making the difficult judgment on who is most likely to benefit from CRT. This decision impacts not only individual patient likelihood of benefit but has major implications on societal costs for this important but expensive therapy.25 What is most remarkable from their findings is that despite the quagmire of various confounding variables and the vagaries of electromechanical coupling, their analysis may cause us to RethinQ how we choose patients for CRT.